{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:03:48Z","timestamp":1790024628281,"version":"4.0.1"},"reference-count":29,"publisher":"Japanese Society of Internal Medicine","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2020,10,1]]},"DOI":"10.2169\/internalmedicine.4705-20","type":"journal-article","created":{"date-parts":[[2020,6,29]],"date-time":"2020-06-29T22:06:14Z","timestamp":1593468374000},"page":"2359-2367","source":"Crossref","is-referenced-by-count":26,"title":["Recommendations for the Management of Neuro-Beh\u00e7et's Disease by the Japanese National Research Committee for Beh\u00e7et's Disease"],"prefix":"10.2169","volume":"59","author":[{"given":"Shunsei","family":"Hirohata","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Nobuhara Hospital, Japan"},{"name":"Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan"},{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotoshi","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Teikyo University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuji","family":"Sawada","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Tokyo Medical University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Okada","sequence":"additional","affiliation":[{"name":"Immuno-Rheumatology Center, St. Luke's International Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuhiro","family":"Takeno","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical University Musashi-Kosugi Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izumi","family":"Kawachi","sequence":"additional","affiliation":[{"name":"Comprehensive Medical Education Center, Niigata University School of Medicine, Japan"},{"name":"Department of Neurology, Brain Research Institute, Niigata University, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Osaka University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Kusunoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kindai University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Ishigatsubo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Hirohata S, Kikuchi H. Beh\u00e7et's disease. Arthritis Res Ther 5: 139-146, 2003.","DOI":"10.1186\/ar757"},{"key":"2","unstructured":"2. Al-Araji A, Kidd D. Neuro-Beh\u00e7et's disease: epidemiology, clinical characteristics, and management. Lancet Neurol 8: 192-204, 2009."},{"key":"3","unstructured":"3. Hirohata S, Kikuchi H, Sawada T, et al. Clinical characteristics of neuro-Behcet's disease in Japan: a multicenter retrospective analysis. Mod Rheumatol 22: 405-413, 2012."},{"key":"4","unstructured":"4. Akman-Demir G, Serdaroglu P, Tasci B; The Neuro-Beh\u00e7et Study Group. Clinical patterns of neurological involvement in Beh\u00e7et's disease: evaluation of 200 patients. Brain 122: 2171-2182, 1999."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Hirohata S, Isshi K, Oguchi H, et al. Cerebrospinal fluid interleukin-6 in progressive neuro-Behcet's syndrome. Clin Immunol Immunopathol 82: 12-17, 1997.","DOI":"10.1006\/clin.1996.4268"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Hirohata S. Potential new therapeutic options for involvement of central nervous system in Beh\u00e7et's disease (neuro-Beh\u00e7et's syndrome). Curr Rheumatol Rev 3: 297-303, 2007.","DOI":"10.2174\/157339707782408973"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Beh\u00e7et's disease. J Neurol Sci 159: 181-185, 1998.","DOI":"10.1016\/S0022-510X(98)00165-8"},{"key":"8","unstructured":"8. Ishido M, Horita N, Takeuchi M, et al. Distinct clinical features between acute and chronic progressive parenchymal neuro-Beh\u00e7et disease: meta-analysis. Sci Rep 7: 10196, 2017."},{"key":"9","unstructured":"9. Hatemi G, Christensen R, Bang D, et al. 2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome. Ann Rheum Dis 77: 808-818, 2018."},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Kikuchi H, Aramaki K, Hirohata S. Low dose MTX for progressive neuro-Beh\u00e7et's disease. A follow-up study for 4 years. Adv Exp Med Biol 528: 575-578, 2003.","DOI":"10.1007\/0-306-48382-3_117"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive neuro-Beh\u00e7et's syndrome. J Neurol Sci 272: 99-105, 2008.","DOI":"10.1016\/j.jns.2008.05.002"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hirohata S, Kikuchi H, Sawada T, et al. Retrospective analysis of long-term outcome of chronic progressive neurological manifestations in Beh\u00e7et's disease. J Neurol Sci 349: 143-148, 2015.","DOI":"10.1016\/j.jns.2015.01.005"},{"key":"13","unstructured":"13. Hibi T, Hirohata S, Kikuchi H, et al. Infliximab therapy for intestinal, neurological, and vascular involvement in Beh\u00e7et disease: Efficacy, safety, and pharmacokinetics in a multicenter, prospective, open-label, single-arm phase 3 study. Medicine (Baltimore) 95: e3863, 2016."},{"key":"14","unstructured":"14. Fukui T, Yamaguchi N, Morizane T, et al. [Medical Information Network Distribution Service (Minds) guidance for development of clinical practice guideline 2014]. Igakushoin, Tokyo, 2014 (in Japanese)."},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Hirohata S, Kikuchi H, Sawada T, et al. Analysis of various factors on the relapse of acute neurological attacks in Beh\u00e7et's disease. Mod Rheumatol 24: 961-965, 2014.","DOI":"10.3109\/14397595.2014.891496"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Noel N, Bernard R, Wechsler B, et al. Long-term outcome of neuro-behcet's disease. Arthritis Rheumatol 66: 1306-1314, 2014.","DOI":"10.1002\/art.38351"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Siva A, Fresko I. Beh\u00e7et's disease. Curr Treat Options Neurol 2: 435-448, 2000.","DOI":"10.1007\/s11940-000-0042-x"},{"key":"18","unstructured":"18. Fujikawa K, Aratake K, Kawakami A, et al. Successful treatment of refractory neuro-Beh\u00e7et's disease with infliximab: a case report to show its efficacy by magnetic resonance imaging, transcranial magnetic stimulation and cytokine profile. Ann Rheum Dis 66: 136-137, 2007."},{"key":"19","unstructured":"19. Di Filippo M, Gregorio MD, Nannini C, et al. Infliximab monotherapy for neuro-Beh\u00e7et's disease: a case report. J Neurol Sci 347: 389-390, 2014."},{"key":"20","unstructured":"20. Pipitone N, Olivieri I, Padula A, et al. Infliximab for the treatment of neuro-Behcet's disease: a case series and review of the literature. Arthritis Rheum 59: 285-290, 2008."},{"key":"21","unstructured":"21. Desbois AC, Addimanda O, Bertrand A, et al. Efficacy of anti-TNF\u03b1 in severe and refractory neuro-Beh\u00e7et disease: An observational study. Medicine (Baltimore) 95: e3550, 2016."},{"key":"22","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","volume":"1","author":"K Masuda","year":"1989","unstructured":"22. Masuda K, Nakajima A, Urayama A, et al. Double-masked trial of cyclosporine versus colchicine and long-term open study of cyclosporine in Beh\u00e7et's disease. Lancet 1: 1093-1096, 1989.","journal-title":"The Lancet","ISSN":"https:\/\/id.crossref.org\/issn\/0140-6736","issn-type":"print"},{"key":"23","doi-asserted-by":"publisher","unstructured":"23. Kotake S, Higashi K, Yoshikawa K, et al. Central nervous system symptoms in patients with Beh\u00e7et's disease receiving cyclosporine therapy. Ophthalmology 106: 586-589, 1999.","DOI":"10.1016\/S0161-6420(99)90120-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Philibert D, Cattran D. Remission of proteinuria in primary glomerulonephritis: we know the goal but do we know the price? Nat Clin Pract Nephrol 4: 550-559, 2008.","DOI":"10.1038\/ncpneph0915"},{"key":"25","unstructured":"25. Ohno S, Nakamura S, Hori S, et al. Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Beh\u00e7et's disease with refractory uveoretinitis. J Rheumatol 31: 1362-1368, 2004."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Zeydan B, Uygunoglu U, Saip S, et al. Infliximab is a plausible alternative for neurologic complications of Beh\u00e7et disease. Neurol Neuroimmunol Neuroinflamm 3: e258, 2016.","DOI":"10.1212\/NXI.0000000000000258"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Kikuchi H, Takayama M, Hirohata S. Quantitative analysis of brainstem atrophy on magnetic resonance imaging in chronic progressive neuro-Beh\u00e7et's disease. J Neurol Sci 337: 80-85, 2014.","DOI":"10.1016\/j.jns.2013.11.020"},{"key":"28","doi-asserted-by":"publisher","unstructured":"28. Akman-Demir G, T\u00fcz\u00fcn E, I\u00e7\u00f6z S, et al. Interleukin-6 in neuro-Behcet's disease: Association with disease subsets and long-term outcome. Cytokine 44: 373-376, 2008.","DOI":"10.1016\/j.cyto.2008.10.007"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Nava F, Ghilotti F, Maggi L, et al. Biologics, colchicine, corticosteroids, immunosuppressants and interferon-alpha for Neuro-Beh\u00e7et's Syndrome. Cochrane Database Syst Rev CD010729, 2014.","DOI":"10.1002\/14651858.CD010729.pub2"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_4705-20\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T03:54:52Z","timestamp":1601697292000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/59\/19\/59_4705-20\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,1]]},"references-count":29,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4705-20","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,1]]}}}